Benzinga

Benzinga

Benzinga

mercredi, août 26

Gilead Sciences Inc

GILDNASDAQ
Trade with Public
Trade with Public
$148.77
2.031.38%
À la clôture: Aug 24, 5:00 PM EST
$148.75
2.011.37%
Pré-ouverture: 7:00 AM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatDividendesComparerOptionsRapport sur les stocks

Gilead Sciences Financials

Gilead Sciences (GILD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est

Gilead Sciences (NASDAQ:GILD) lowers FY2026 GAAP EPS guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) analyst estimate..
Benzinga Newsdesk

PRO
Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est

Gilead Sciences (NASDAQ:GILD) raises FY2026 Adj EPS guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) analyst estimate. Raises FY2026 sales outlook from $30.000 billion-$30.400 billion to $30.100
Benzinga Newsdesk

PRO
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate

Gilead Sciences (NASDAQ:GILD) reported quarterly losses of $(6.75) per share which beat the analyst consensus estimate of $(7.24) by 6.64 percent. This is a 435.82 percent decrease over earnings of $2.01 per share from
Benzinga Newsdesk

PRO
Gilead Sciences Raises FY2026 Sales Guidance from $29.600B-$30.000B to $30.000B-$30.400B vs $30.216B Est

Guidance and OutlookFor the full year 2026, Gilead now expects:(in millions, except per share amounts) May 7, 2026 Guidance Comparison to February 10, 2026 Guidance Low EndHigh EndProduct
Benzinga Newsdesk

PRO
Gilead Sciences Lowers FY2026 Adj EPS Guidance from $8.45-$8.85 to $(1.05)-$(0.65) vs $8.66 Est

GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)(unaudited)     (in millions, except percentages and per share amounts) Provided February 10,
Benzinga Newsdesk

PRO
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $6.75-$7.15 to $(3.25)-$(2.85) vs $7.51 Est

GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)(unaudited)     (in millions, except percentages and per share amounts) Provided February 10,
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved